← All trials
NCT04641195
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2021
- Primary completion
- Nov 30, 2021
- Completion date
- Mar 31, 2022
- First posted
- Nov 23, 2020
- Last posted
- Apr 27, 2021
- Enrollment
- 700
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Harvard UniversityLead sponsor
- University of TorontoCollaborator
- Harvard UniversityReponsible party - principal investigator
- Harvard UniversityOverall official - principal investigator
- Foundation for Medical ResearchCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.